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Background: Acute coronary syndromes account for half of all deaths secondary to cardiovascular disease
and represent a signiﬁcant economic burden in the United States. Therefore, assessing hospitalization costs
relative to Medicare reimbursement for these patients is important in understanding the impact of these
patients on hospitals. We hypothesized that hospitalization costs for acute myocardial infarction patients
treated with percutaneous coronary intervention (PCI) were higher than their associated Medicare payments.
Methods: Using the Nationwide Inpatient Sample, we evaluated hospitalization costs for patients treated
with PCI from 2001 through 2009 by multiplying hospital charges by the group average cost-to-charge ratio
for each patient’s hospitalization. Primary end points examined were total hospital costs and trends over
time, which were correlated with clinical outcomes and insurance payments. Costs were inﬂation adjusted
with 2009 as the reference year.
Results: Median hospitalization costs of PCI increased from $15 889 (interquartile range [IQR]=$12 057–
$21 204) in 2001 to $19 349 (IQR=$14 660–$26 282) in 2009. From 2004 to 2009, inﬂation-adjusted costs for
PCI decreased at a rate of 0.3% per year. In 2009, a total of 265,531 patients received PCI for acute myocardial
infarction. Of these, 143 654 were <65 years old, and 121 876 were ≥65 years old. Average 2009 Medicare
payments ranged from $9303 to $17 500 depending on the Medicare Severity-Diagnosis Related Groups
(MS-DRG) billed, leaving hospitals at a loss of anywhere from $4493 to $7940 per patient when comparing
costs and reimbursements across all included MS-DRG codes.
Conclusions: Hospitalization costs for patients treated with PCI have been stabilizing over the last few years;
however, there still remains a signiﬁcant disparity between Medicare reimbursements and hospitalization
costs, which has potential implications on patient outcomes, quality of care, and hospital sustainability.
Introduction
Although cardiovascular disease mortality rates have slowly
declined in the United States, they still remain the leading
cause of death in both men and women.1 Acute coronary syn-
dromes, which include unstable angina, non–ST-segment
elevation myocardial infarction (NSTEMI), and ST-segment
elevation myocardial infarction (STEMI), account for half
of all deaths due to cardiovascular disease.2 Given the large
number of admissions for acute coronary syndromes, it
is important to assess the economic impact these patients
have on hospitals. Furthermore, it is essential to understand
hospitalization costs, because Medicare payments may not
be adequately reimbursing costs of treatment. Therefore, in
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this study, we used the Nationwide Inpatient Sample (NIS)
data to describe recent hospitalization costs associated
with percutaneous coronary intervention (PCI) for acute
myocardial infarction (AMI), and examined the trends in
these costs over time, along with the relationship between
costs and Medicare payments in 2009.
Methods
Patient Population
We collected and analyzed data from the NIS hospital
discharge database for the period January 1, 2001 through
December 31, 2009, which was acquired from the Healthcare
Cost and Utilization Project of the Agency for Healthcare
Research and Quality in Rockville, Maryland.3 The NIS is
a hospital discharge database that represents 20% of all
inpatient admissions to nonfederal hospitals in the United
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States. Using the NIS for years 2001 through 2009, patients
who underwent PCI were identified using the International
Classification of Diseases, 9th Revision (ICD-9) procedure
codes 0066, 3603, 3604, 3606, 3607, 3609. Of these patients,
we selected those with a primary ICD-9 diagnosis code of
NSTEMI (41070, 41071) or STEMI (41000, 41001, 41010,
41011, 41020, 41021, 41030, 41031, 41040, 41041, 41050,
41051, 41060, and 41061).
Cost Data
We determined an association between the following
variables and total costs in the 2009 sample: age, gender,
discharge status (home/short-term facility, long-term
facility, and in-hospital death), primary payer (Medicare,
Medicaid, private insurance, self-pay, no charge, other),
race, patient household income quartile (based on the
patients’ home zip codes), Charlson Comorbidity Index
(CCI), procedure type (drug-eluting stent, bare-metal stent,
angioplasty without stenting), intensive care unit (ICU)
stay, hospital region (Northeast, Midwest, South, West),
hospital location/teaching status (rural, urban nonteaching,
urban teaching), and hospital bed size (small, medium,
large). Mechanical ventilation (ICD-9 procedure codes 9670-
9672), was used as a surrogate for ICU stay. Hospitalization
costs were determined by taking the total hospitalization
charges and multiplying them by the group average cost-
to-charge ratio (CCR) for each patient’s hospitalization.
Hospitalization charges and CCR were provided by the
NIS database.
The NIS database provides data on the total hospitalization
charges and the CCR. These charges represent the amount
that hospitals billed for their services, but do not reflect how
much the services actually cost or the specific amounts that
hospitals received in payment. The CCR allows one to see
how hospital charges translate into actual costs.4 The CCRs
provided are based on all-payer inpatient cost, which was
obtained from accounting reports collected by the Centers
for Medicare & Medicaid Services.
We examined trends in inflation-adjusted hospitalization
costs of PCI for AMI from 2001 through 2009. To
account for inflation we used the general consumer
price index calculator (available at http://data.bls.gov/cgi-
bin/cpicalc.pl) and converted all costs and charges to their
dollar value in 2009.
Comparison With Medicare Reimbursements
For patients whose hospitalization was paid for by Medicare
in 2009, we compared the cost of hospitalization to mean
Medicare payments for the Medicare Severity-Diagnosis
Related Groups (MS-DRG) of the hospitalization. Diagnosis
Related Groups (DRGs) included in our study were 246
(percutaneous cardiovascular procedure with drug-eluting
stent with major complication or comorbidity or 4+ vessels/
stents), 247 (percutaneous cardiovascular procedure with
drug-eluting stent without major complication or comor-
bidity), 248 (percutaneous cardiovascular procedure with
non–drug-eluting stent with major complication or comor-
bidity or 4+ vessels/stents), 249 (percutaneous cardio-
vascular procedure with non–drug-eluting stent without
major complication or comorbidity), 250 (percutaneous
cardiovascular procedure without coronary artery stent
with major complication or comorbidity), 251 (percuta-
neous cardiovascular procedure without coronary artery
stent without major complication or comorbidity). These
DRGs were applied only to patients who suffered from an
AMI requiring PCI. Medicare payments are public informa-
tion (http://www.cms.hhs.gov).
Statistical Analysis
We used the nonparametric Wilcoxon rank sum test to
determine statistical significance, defined as a P value
<0.05. We also present medians and interquartile ranges.
Multivariate analysis to determine predictors of cost for
patients in 2009 was performed using a standard least
squares model. Variables included in the model were age,
gender, race, discharge status, procedure type, NSTEMI vs
STEMI, insurance status, zip income quartile, CCI, hospital
region, hospital location/teaching status, hospital bed size,
and ICU stay. All potential predictors of cost were forced
into the model. Given that the study involved publically
available, coded information that could not be linked to
specific individuals directly or indirectly, this study was
felt to be exempt from institutional review board approval.
All statistical analysis was performed using the SAS-based




Cost data from 2009 were available for a total of 265 531
patients. Of these, 137 863 patients suffered a STEMI
(51.9%) and 127 668 suffered a NSTEMI (48.1%). In terms
of age, 143 654 (54.1%) were younger than 65 years, and
121 876 (45.9%) were ≥65 years. In regard to discharge
status, 247 194 (93.1%) patients were discharged to home/
short-term facility, 13 183 (5.0%) patients were discharged
to long-term facilities, and 5055 (1.9%) patients suffered in-
hospital mortality. There were 11 192 (4.2%) patients who
required mechanical ventilation.
Hospital Data
Of the 265 531 hospitalizations for AMI, the majority of
these were located in the Southern United States, in urban
settings, and in large–bed-size hospitals. Specific details of
hospital data can be seen in Table 1.
Hospitalization Costs in 2009
Cost data are also summarized in Table 1. The median cost
for all patients hospitalized in 2009 was $19 349 (interquartile
range [IQR] = $14 660–$26 282). There was a significant
difference in the median costs for patients <65 years old
compared to≥65 years old (P < 0.0001). Patients discharged
to home or short-term facilities had significantly lower
median costs when compared to those patients discharged
to long-term facilities ($18 949 vs $30 007, P < 0.0001).
Costs varied significantly by primary payer, with Medicare
patients having the highest median costs compared to
those with no charge or self-pay. Patients receiving drug-
eluting stents had significantly higher costs than patients
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Table 1. Hospital Costs Data in 2009
Variable No. (%) Median Cost, US$ IQR, US$ P
All patients 265 531 19 349 14,660–26,282 —
Age
<50 years 43 914 (16.5) 18 327 14,067–24,518 <0.0001
50–64 years 99 740 (37.5) 19 003 14,473–25,486
65–80 years 81 987 (30.9) 19 875 14,956–27,187
80+ years 39 889 (15.0) 20 625 15,358–28,361
Gender
Male 179 944 (67.8) 19 183 14,599–25,937 <0.0001
Female 85 582 (32.2) 19 670 14,791–27,010
Discharge status
Home/short term 247 194 (93.1) 18 949 14,470–25,396 <0.0001
Long term 13 183 (5.0) 30 007 20,736–46,577
Death 5 055 (1.9) 27 882 18,519–45,589
Insurance status
Medicare 115 442 (43.5) 20 079 15,064–27,488 <0.0001
Medicaid 15 495 (5.8) 19 813 14,470–27,277
Private insurance 99 497 (37.5) 18 987 14,544–25,463
Self-pay 22 891 (8.6) 17 752 13,320–23,894
No charge 2 057 (0.8) 17 583 14,608–22,008
Other 9 469 (3.6) 19 228 14,985–25,927
Race
White 164 956 (62.1) 18 637 14,114–25,383 <0.0001
Black 18 258 (6.9) 18 228 13,693–25,145
Hispanic 15 019 (5.7) 20 542 15,168–28,775
Asian 4 770 (1.8) 24 476 16,492–35,643
Income quartilea
1 (lowest) 69 898 (26.3) 18 568 14,029–25,125 <0.0001
2 73 064 (27.5) 19 134 14,625–25,957
3 64 847 (24.4) 19 713 14,871–26,905
4 (highest) 50 985 (19.2) 20 439 15,597–27,881
Charlson Comorbidity Index
1 124 867 (47.0) 18 225 14,013–24,251 <0.0001
2 76 150 (28.7) 19 375 14,758–26,198
3 36 221 (13.6) 21 052 15,660–28,820
≥4 28 293 (10.7) 23 788 17,067–33,338
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Table 1. Continued
Variable No. (%) Median Cost, US$ IQR, US$ P
STEMI vs NSTEMI
STEMI 127 668 (48.1) 19 639 14,998–26,345 <0.0001
NSTEMI 137 863 (51.9) 19 087 14,341–26,216
Procedure type
Drug-eluting stent 169 073 (63.7) 20 016 15,250–26,898 <0.0001
Bare-metal stent 76 585 (28.8) 18 269 13,869–24,902
Angioplasty, no stent 20 275 (7.6) 17 876 13,189–25,771
ICU stay
Yes 11 192 (4.2) 34 752 24,058–54,841 <0.0001
No 254 339 (95.8) 19 026 14,510–25,552
Hospital region
Northeast 31 654 (11.9) 18 232 12,743–25,389 <0.0001
Midwest 68 847 (25.9) 20 089 16,052–26,184
South 117 079 (44.1) 17 695 13,487–23,862
West 47 951 (18.1) 23 843 17,481–32,606
Hospital location
Rural 16 946 (6.4) 22 834 18,491–28,485 <0.0001
Urban nonteaching 109 007 (41.1) 19 421 15,041–26,458
Urban teaching 139 578 (52.6) 18 769 13,903–25,799
Hospital bed size
Small 15 409 (5.8) 22 171 16,741–29,080 <0.0001
Medium 47 459 (17.9) 18 872 13,957–25,774
Large 202 663 (76.3) 19 236 14,690–26,188
Abbreviations: ICU, intensive care unit; IQR, interquartile range. NSTEMI, non–ST-segment elevation myocardial infarction; STEMI, ST-segment elevation
myocardial infarction.
aMedian household income quartiles for patient’s zip codes are deﬁned as: (1) $1–$38 999; (2) $39 000– $47 999; (3) $48 000–62 999; and (4) $63 000
or more.
receiving bare-metal stents and those receiving angioplasty
without stenting. Hospital location, region, and bed size also
showed differences in cost, with the Western United States
region, rural locations, and small–bed-size hospitals having
significantly higher costs (P < 0.0001).
Predictors of Cost With Multivariate Analysis
When performing our multivariate analysis, we found
that age, female gender, discharge to long-term facility,
insurance status (true for public insurance vs private
insurance, and private insurance vs self-pay), race, income
quartile, procedure type, hospital region, hospital location/
teaching status, hospital bed size, and ICU stay were
independent predictors of increased costs (P < 0.0001).
Charlson Comorbidity Index was also an independent
predictor of increased costs (P = 0.0005)
Medicare Population: Costs ComparedWith Reimbursement
For 2009, average Medicare payments for PCI for AMI
were substantially lower than median hospitalization costs
for Medicare patients for MS-DRGs 246–251. Differences
in costs and reimbursement ranged from $4493 for MS-
DRG 250 to $7940 for MS-DRG 247. Mean Medicare
reimbursements were lower than the 25th percentile of
costs for MS-DRGs 246, 247, 248, 249, and 251. These data
are summarized in Table 2.
Cost Trends Over Time
Between 2001 and 2009, cost data were available for 2 148 861
patients. Trends in costs for treatment of AMI with PCI
are summarized in Figure 1. Between 2001 and 2009, the
inflation-adjusted cost for hospitalization for treatment of
AMI with PCI increased from $15 889 (IQR = 12 057–21 204)
to $19 349 (IQR = 14 659–26 281). Between 2001 and 2004,
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Table 2. Medicare Patients Costs vs Reimbursements in 2009






246 22 829 25 000 18 614–33 751 17 500 7500
247 47 130 18 750 14 611–24 565 10 810 7940
248 12 316 23 038 16 919–32 288 16 066 6972
249 20 265 16 953 13 078–22 112 9520 7433
250 2919 20 066 14 643–27 946 15 573 4493
251 4755 15 609 11 956–20 382 9303 6306
Abbreviations: DRG, Diagnosis Related Group; IQR, interquartile range.
inflation-adjusted costs for PCI in AMI increased at an
average rate of 7.4% per year. From 2004 to 2009, inflation-
adjusted costs for PCI decreased at a rate of 0.3% per year.
Discussion
Overall, the median hospitalization costs for patients
undergoing PCI for acute coronary syndromes have
increased from $15 889 in 2001 to $19 349 in 2009,
but costs were steady from 2004 to 2009 (Figure 1).
Medicare payments have not been adequate in reimbursing
hospitalization costs, rendering hospitals at an average loss
of anywhere between $4493 (MS-DRG 250) and $7940
(MS-DRG 247) in 2009. Considering that Medicare was
the primary payer for approximately 43.5% of patients in
this study, it is clear that these losses create a significant
economic burden on hospitals.
Riley et al recently assessed the trends in coronary
revascularization over the 2001 to 2009 period and showed
an average year-to-year increase in PCI volume of 1.3% per
1000 Medicare beneficiaries.5 The increasing population of
Medicare beneficiaries receiving PCI, along with systematic
under-reimbursement, shall only further burden hospitals.
The increase in costs between 2001 and 2004 may be
attributed to the advent of the drug-eluting stent. Drug-
eluting stents have been widely popular since US Food &
Drug Administration approval in early 2003. In our study we
found that costs increased significantly between 2002 and
2003, when drug-eluting stents were starting to be widely
utilized, and again between 2003 and 2004, when drug-
eluting stents were first available for an entire year. The role
of drug-eluting stents on increased costs is further supported
by the fact that in 2009, patients receiving drug-eluting
stents had significantly higher hospitalization costs than
their bare-metal stent and balloon angioplasty counterparts.
Our study demonstrated a decline in median hospitalization
costs between 2004 and 2009.
Although not addressed in this study, other studies
demonstrate that rehospitalizations during the 1-year follow-
up after PCI also pose significant cost as well.6 This
could potentially add to the cost-payment discrepancies
described in this study. Several studies have described the
overall cost fluctuations to the Medicare program over the
study period7,8; however, to the best of our knowledge,
Figure 1. Median hospitalization cost trend from 2001 to 2009. Median
hospitalization costs for patients undergoing PCI for acute coronary
syndromes have increased from 2001 to 2009. Costs have been steady
from 2004 to 2009. The conﬁdence bands with each data point represent
the 25th and 75th quartiles.
this present study represents the first examination of
index hospitalization costs and payments for PCI in
acute coronary syndromes. Similar cost studies analyzing
endovascular treatments in patients with acute ischemic
stroke and unruptured cerebral aneurysms have also
shown that Medicare payments are not sufficiently meeting
hospitalization costs,9,10 a predicament that needs further
attention.
In the era of dramatic changes to the healthcare economic
landscape, such as the Balanced Budget Act (BBA) of
1997, and more recently the Affordable Care Act (ACA) of
2010, Medicare payment implications on hospital quality
of care and patient outcomes has become a hot topic
of discussion. Authors Shen and Wu have shown that
hospitals facing large payment cuts experienced slower
improvement in patient mortality rates in the post-BBA
period with relation to AMI patient outcomes, relative
to those facing small payment cuts, and that Medicare
price cuts lead to reduced staffing and operating expenses,
which they tied to increases in patient mortality rates.11,12
Bazzoli et al have published several studies showing that
BBA has adversely affected hospitals’ financial conditions,
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and that hospitals with worse financial condition ultimately
had to curtail investments in important areas, such as
infrastructure, nursing staff, patient support and safety
services, and quality-enhancing activities.13–15 White and
Wu performed a unique analysis looking at the long-
term effect of BBA, studying the period of 1996 through
2009 and excluding small rural hospitals, allowing time
to appropriately adjust to the Medicare payment changes.
They concluded that hospitals’ total revenues will drop
under the ACA by more than expected based on just
Medicare price changes, and that a significant percentage
of lost revenues will be offset by reduced operating
expenses, mainly via savings on personnel, but also
nonpersonnel costs, along with delaying or forgoing capital
improvements.16 Volpp et al have previously shown that the
BBA did not have a significant impact on 30-day mortality
in AMI, but suggested that in the long run, reductions
in margins could potentially translate into reductions
in capital investments, infrastructure improvements, and
quality-improvement initiatives that could reduce the rate
of improvement in care.17 These are important points to
consider, as the BBA and ACA both lower hospital spending
primarily by reducing DRG payment increases; however,
the rate of payment reduction as part of the ACA is actually
larger than the BBA, with the ACA reducing DRG payment
by an estimated 1.1% per year indefinitely vs the BBA, which
reduced Medicare inpatient payment by 5% between 1998
and 2000.18,19
We also demonstrated that insurance status was
significantly associated with hospitalization costs when
controlling for age, gender, comorbidities, and outcomes.
Patients who had Medicare or Medicaid as the primary
payer had significantly higher hospitalization costs than
patients with private insurance, and privately insured
patients had a higher cost than those who were uninsured.
The significance of higher hospitalization costs for patients
on public insurance is unclear. The association of higher
cost with race may be related to other unmeasured
comorbidities, whereas the association with income status
remains unclear and requires further study and elucidation.
This may be due to a number of factors including differences
in resource utilization during the hospitalization based off
of insurance status and income. We cannot exclude the
interaction of other factors not measured in this database.
Differences in costs and charges by insurance status have
been demonstrated in previous studies.20
Although not the major focus of this current study,
literature regarding performing transradial percutaneous
coronary intervention (TRPCI) over transfemoral percuta-
neous coronary intervention (TFPCI) has been growing in
interest.21 A recent meta-analysis of randomized controlled
trials comparing TRPCI vs TFPCI in STEMI patients showed
that TRPCI had a statistically significant 48% reduced risk
of major bleeding, 42% reduced risk of mortality, and a 33%
reduced risk of major adverse cardiac event. This study
also showed a significantly shorter hospital stay in the
transradial group, but also higher frequency of access site
crossover and a non–statistically significant longer time to
reperfusion.22 The implications of that meta-analysis can be
considered in light of other recent studies that assess the
hospitalization costs of TRPCI vs TFPCI, and have found
that TRPCI was associated with lower average total costs of
care, primarily driven by reduced length of stay and bleed-
ing complications.23 Recent work has estimated that TRPCI
results in approximately $730 to $800 savings per PCI pro-
cedure, which when compared to TFPCI could amount to
significant reductions in annual hospitalizations costs.24,25
Although the transfemoral approach remains the most com-
monly used technique, further studies regarding transradial
PCI could potentially help with the problem of determining
ways of reducing hospitalization costs.
Coding errors are a potential limitation of this study,
as they are with any study using a large administrative
database. However, the very large numbers in this database
should minimize that limitation. Another potential limitation
is our use of CCRs in determining hospitalization costs. A
hospital CCR is a reflection of a hospital’s annual total costs
divided by the annual total charges. The major components
of hospital costs that can be included in a hospital CCR
include the cost of devices and pharmaceuticals, employee
costs (nurses, pharmacists, physicians, technologists), and
malpractice insurance. Other ancillary costs that are
components of CCR include building costs, maintenance
costs, outpatient services, hospital investments, and loan
repayments. Thus, some components of the cost of
hospitalizations are not directly related to patient care but
rather to institutional expenses, such as investments and
loan repayments, that are distributed among the patient
population.
In our study, we used average nationwide reimbursement
rates for the 6 procedure-related DRG codes in calculating
the disparities between costs and reimbursement. Hospitals
receive different payments for DRGs depending on their
location, teaching status, and case mix. We were able to
show significant differences in costs based on hospital
region, location/teaching status, and bed size; however,
we could not obtain data on DRG reimbursement rates
for specific hospitals, as these data are not available.
Nonetheless, given the differences between hospitalization
costs of Medicare patients in this study and the amount that
Medicare reimbursed, on average, it is reasonable to assume
that failure to reimburse for costs based on these CCRs
caused hospitals to lose a considerable amount of money
that could be invested into patient care. Furthermore, the
costs and reimbursements addressed here refer specifically
to index hospitalizations, and do not include out-of-hospital
or follow-up costs for patients undergoing PCI, which can
potentially contribute significantly to the overall costs of
care. The costs of PCI also refer to all PCI procedures and
do not differentiate between which access site was used.
Cost trends discussed in this study were not compared
with payment trends over the entire study period, as the
most recent year included was felt sufficient to represent a
clear disparity. Finally, the mean Medicare payments were
reported rather than individual payments. This may affect
the accuracy of the reported payments; however, the means
should be a good reflection of general trends given the large
sample size studied.
Conclusion
Our study of the NIS shows that not only have the
hospitalization costs for PCI in acute coronary syndromes
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been stabilizing over the recent studied years, but more
importantly, Medicare payments clearly have not been
adequately reimbursing these hospitalizations. Therefore,
for hospitals to maintain economic stability in caring for
these patients, strident efforts should be made to both
significantly reduce hospitalization costs and encourage
Medicare to adequately reimburse hospitals for the services
that they provide. Interesting nonclinical predictors of
cost are noted and deserve further study and analysis.
Furthermore, past experiences with the BBA of 1997 may
help predict long-term implications of the ACA of 2010
on hospital outcomes, quality of care, and sustainability.
Further analysis of the impact of the ACA on hospitals will
be important to conduct, especially with common conditions
that require hospitalizations such as AMI.
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